Frequency and Detectability of Uncommon EGFR Mutations in NSCLC

被引：0
|
作者：
O'Sullivan, H. M. [1 ]
MacMahon, S. [1 ]
Cui, W. [1 ,2 ]
Milner-Watts, C. [1 ]
Tokaca, N. [1 ]
Bhosle, J. [1 ]
Davidson, M. [1 ]
Minchom, A. [1 ]
Yousaf, N. [1 ]
O'Brien, M. [1 ,3 ]
Popat, S. [1 ,3 ,4 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Peter MacCallum Canc Ctr, Melbourne, Australia
[3] Imperial Coll London, Natl Heart & Lung Inst, London, England
[4] Inst Canc Res, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR; Next Generation Sequencing; PCR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA12.09
引用
收藏
页码：S88 / S89
页数：2
相关论文
共 50 条
  • [31] A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib: focus on Asian patients
    Miura, Satoru
    Schuler, Martin
    Popat, Sanjay
    Park, Keunchil
    Passaro, Antonio
    De Marinis, Filippo
    Solca, Flavio
    Maerten, Angela
    Kim, Edward S.
    Yang, James Chih-Hsin
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S500 - S500
  • [32] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [33] EGFR EXON 20 INSERTION MUTATIONS IN NSCLC: FREQUENCY AND TREATMENT OUTCOMES WITH EGFR DIRECTED TKIS
    Ovcaricek, T.
    Unk, M.
    Kern, I.
    Cufer, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S64 - S64
  • [34] Unarranged territory in uncommon EGFR mutations
    Fujii, Hiroyuki
    Okuma, Yusuke
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1233 - 1236
  • [35] Is There a Unicorn Among the Uncommon EGFR Mutations?
    Tan, Wan Ling
    Lim, Darren Wan-Teck
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 129 - 132
  • [36] Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
    Christopoulos, Petros
    Herster, Franziska
    Hoffknecht, Petra
    Falk, Markus
    Tiemann, Markus
    Kopp, Hans-Georg
    Althoff, Andre
    Stammberger, Anja
    Laack, Eckart
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy
    Jinpeng Shi
    Hui Yang
    Tao Jiang
    Xuefei Li
    Chao Zhao
    Limin Zhang
    Sha Zhao
    Xiaozhen Liu
    Yijun Jia
    Yan Wang
    Lei Xi
    Shijia Zhang
    Chunxia Su
    Shengxiang Ren
    Caicun Zhou
    [J]. Chinese Journal of Cancer Research, 2017, 29 (06) : 543 - 552
  • [38] Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
    Passaro, Antonio
    Mok, Tony
    Peters, Solange
    Popat, Sanjay
    Ahn, Myung-Ju
    de Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 764 - 773
  • [39] FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)
    Le, Xiuning
    Spira, Alexander I.
    Gadgeel, Shirish M.
    Riess, Jonathan W.
    Yu, Yan
    Zhao, Yanqiu
    Cheng, Ying
    Juan-Vidal, Oscar
    Gao, Bo
    Yoh, Kiyotaka
    Forster, Martin
    Kitazono, Satoru
    Hayashi, Hidetoshi
    Planchard, David
    Jiang, Yong
    Baio, Nichole
    Kowanetz, Marcin
    Leung, William
    Hsu, Jerry Y.
    Wang, Jie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
    Fang, W. F.
    Bu, Q.
    Wang, Q. M.
    Zhao, W. H.
    Wang, L. P.
    Dong, X. R.
    Chen, P. F.
    Wen, Z. B.
    Jia, J.
    Jiang, G. M.
    Zhang, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S333 - S334
12345